Case Report
Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Sep 26, 2019; 7(18): 2905-2909
Published online Sep 26, 2019. doi: 10.12998/wjcc.v7.i18.2905
Guillain-Barré syndrome in a patient with multiple myeloma after bortezomib therapy: A case report
Yu-Ling Xu, Wei-Hua Zhao, Zhong-Yuan Tang, Zhong-Qing Li, Yuan Long, Peng Cheng, Jun Luo
Yu-Ling Xu, Wei-Hua Zhao, Zhong-Yuan Tang, Zhong-Qing Li, Yuan Long, Peng Cheng, Jun Luo, Department of Hematology, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China
Author contributions: Xu YL wrote and revised the manuscript; Zhao WH and Tang ZY collected the clinical data; Li ZQ, Long Y, and Cheng P provided information consultation; Luo J reviewed the manuscript; all authors read and approved the final manuscript.
Supported by National Natural Science Foundation of China, No. 81660038.
Informed consent statement: Informed consent was obtained from the patient for this publication.
Conflict-of-interest statement: The authors declare that they have no competing interests.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Jun Luo, PhD, Chief Doctor, Professor, Department of Hematology, the First Affiliated Hospital of Guangxi Medical University, No. 6, Shuangyong Road, Nanning 530021, Guangxi Zhuang Autonomous Region, China. luojungz@medmail.com.cn
Telephone: +86-13877179705
Received: April 11, 2019
Peer-review started: April 12, 2019
First decision: August 1, 2019
Revised: August 13, 2019
Accepted: August 26, 2019
Article in press: August 26, 2019
Published online: September 26, 2019
Core Tip

Core tip: Multiple myeloma (MM) is a malignant clonal disease, which shortens the survival time of the patients. Bortezomib, a first-line drug for the treatment of MM, has prolonged patient survival. Therefore, the adverse reactions have become a hot topic. We can have a better understanding of its complications and treatment through this case.